|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Walgreen Company (NYSE:WAG), a major drugstore chain. |
|---|---|
| Transferring Party | Option Care, Inc. (NASDAQ:OPTN), a national provider of specialty pharmacy and home infusion services. |
| Sector | Medical Services |
| Date | July 2, 2007 |
| Analysis Strengthens Walgreen's position as a full-service specialty pharmacy provider, especially in areas such as hemophilia, immune deficiency and oncology. The deal allows Walgreen to provide a lower-cost alternatives for pharmaceutical and infusion services. Walgreen recently consolidated several pharmaceutical services companies: Take Care Health Systems, a leading operator of convenient care clinics, Medmark Specialty Pharmacy Solutions, a full-service, national specialty pharmacy company, SeniorMed Pharmacy, which provides prescription services to residents in assisted-living, specialty care and independent communities across the country and Schraft’s A Specialty Pharmacy, one of the nation’s leading providers of advanced fertility medications and services. Deal value - $850m, based on revenue of $715.7m (1.19x) and EBITDA of $48.1m (17.7x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |